BLAINJECTIONINJECTABLE
Approved
Dec 2021
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
ADBRY (tralokinumab-ldrm) by Leo Pharma is interleukin-13 antagonists [moa]. First approved in 2021.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ADBRY (tralokinumab-ldrm) is a fully human monoclonal antibody that selectively blocks interleukin-13 (IL-13), a key cytokine driving type 2 inflammatory responses. It is approved for moderate-to-severe atopic dermatitis in adults. The drug targets the underlying immunologic drivers of atopic disease rather than just symptomatic relief.
$32MPart D
PeakADBRY is in peak commercial phase with $32M in Part D spending (2023), indicating solid market penetration, though team growth may be moderate given competitive intensity in the IL-13 antagonist space.
Mechanism of Action
Interleukin-13 Antagonists
Pharmacologic Class:
Interleukin-13 Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ADBRY offers career opportunities in a mature, competitive immunology franchise with strong safety/efficacy data and solid commercial traction ($32M Part D spend). Professionals should expect roles focused on market defense, payer education, and real-world outcomes rather than high-growth launch infrastructure.
Brand ManagerMedical Science Liaison (MSL)
Worked on ADBRY at Leo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.